Mucinous borderline ovarian tumors: pathological and prognostic study at Salah Azaiez Institute.
Mucinous tumor
borderline ovarian tumor
primary tumor
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
11
2021
accepted:
10
04
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
3
8
2022
Statut:
epublish
Résumé
ovarian Mucinous Borderline Tumors (MBT) are characterized by an epithelial proliferation similar to those of well differentiated adenocarcinomas but are distinguished by the absence of stromal invasion. They are often difficult to diagnose histologically. The aim of the work was to specify the pathological and clinical features and to highlight the prognostic of these tumors. study was retrospective including 49 cases of primary ovarian MBT, diagnosed at the Patholgy Department of Salah Azaiez Institute from 1992 to 2019. median age was 48 years old. Histologically, the cases were divided into 34 cases of pure MBT, 13 cases with intraepithelial carcinoma and 2 cases associating an intraepithelial carcinoma with microinvasion. The majority of our cases were classified FIGO I and only one case FIGO III. Sixteen patients received conservative treatment and 30 received radical treatment. The treatment wasn't specified in three patients. The prognosis was good in the majority of cases. Only one patient had a contralateral recurrence after a follow-up period of three years. There were no significant differences regarding the risk of recurrence and risk factors such as age, gestation, hormonal status, FIGO stage and conservative treatment. We raised this part. the prognosis of the ovarian MBT is good. However, it is necessary to multiply the samples to avoid missing a carcinomatous focus with an anarchic invasion of the stroma which constitutes a poor prognosis factor. It was changed by these sentences below: the diagnosis of MBT is not easy. Indeed, the distinction of MBT from carcinomas remains the greatest challenge for pathologists. Once this diagnosis is made with certainty, the tumor can be considered to have a good prognosis, especially stage I tumors which are the most common.
Identifiants
pubmed: 35909430
doi: 10.11604/pamj.2022.41.349.32332
pii: PAMJ-41-349
pmc: PMC9279460
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349Informations de copyright
Copyright: Ghada Sahraoui et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Am J Surg Pathol. 2007 Apr;31(4):546-54
pubmed: 17414101
Cancer. 1988 Jan 15;61(2):340-8
pubmed: 3334969
Int J Gynecol Pathol. 2011 May;30(3):218-30
pubmed: 21464732
Arch Pathol Lab Med. 2008 Nov;132(11):1753-60
pubmed: 18976011
Hum Pathol. 2004 Aug;35(8):918-33
pubmed: 15297960
Int J Gynecol Cancer. 2012 Jun;22(5):770-7
pubmed: 22426410
Cancer. 1985 May 1;55(9):1958-62
pubmed: 2983869
Mod Pathol. 2006 Jan;19(1):97-105
pubmed: 16294196
Am J Surg Pathol. 2006 Sep;30(9):1130-9
pubmed: 16931958
Virchows Arch. 2017 Feb;470(2):125-142
pubmed: 28025670
Am J Surg Pathol. 2008 Mar;32(3):383-9
pubmed: 18300813
Am J Surg Pathol. 2002 Nov;26(11):1467-76
pubmed: 12409723
Hum Pathol. 2004 Aug;35(8):949-60
pubmed: 15297962
Cancer. 2001 Jul 1;92(1):85-91
pubmed: 11443613
Int J Gynecol Pathol. 2005 Jan;24(1):4-25
pubmed: 15626914
Int J Gynecol Pathol. 2010 Mar;29(2):108-12
pubmed: 20173495
Oncologist. 2012;17(12):1515-33
pubmed: 23024155
Ann Pathol. 2014 Feb;34(1):9-13
pubmed: 24630632
Int J Gynecol Pathol. 2006 Jan;25(1):83-9
pubmed: 16306790
J Pathol. 2015 Oct;237(2):146-51
pubmed: 26095692
Mod Pathol. 2005 Feb;18 Suppl 2:S33-50
pubmed: 15761465
Pathol Int. 1996 Aug;46(8):575-80
pubmed: 8893226
Am J Surg Pathol. 1998 Dec;22(12):1449-62
pubmed: 9850171
Am J Surg Pathol. 1999 Jun;23(6):617-35
pubmed: 10366144
Am J Surg Pathol. 1994 Jun;18(6):591-603
pubmed: 8179074
Am J Surg Pathol. 2000 Nov;24(11):1447-64
pubmed: 11075847
Am J Surg Pathol. 2003 May;27(5):650-7
pubmed: 12717249
Am J Surg Pathol. 2003 Aug;27(8):1089-103
pubmed: 12883241
J Pediatr Adolesc Gynecol. 2018 Feb;31(1):48-54
pubmed: 28899828
Int J Gynecol Pathol. 1992;11(1):58-62
pubmed: 1563909
Am J Surg Pathol. 1991 May;15(5):415-29
pubmed: 2035736
Am J Surg Pathol. 2002 Feb;26(2):139-52
pubmed: 11812936
Gynecol Oncol. 2016 Jul;142(1):50-53
pubmed: 27168006
J Pathol. 2013 Jan;229(1):111-20
pubmed: 22899400
Int J Gynecol Pathol. 2011 Jan;30(1):4-11
pubmed: 21131840
Gynecol Obstet Invest. 2018;83(1):45-51
pubmed: 28571024
Gynecol Obstet Invest. 2015 Jun 6;:
pubmed: 26067608
Cancer. 1973 May;31(5):1031-45
pubmed: 4735836
Am J Surg Pathol. 2011 Jun;35(6):816-26
pubmed: 21552115
Int J Gynecol Pathol. 2002 Oct;21(4):391-400
pubmed: 12352188
Int J Gynecol Cancer. 2018 Nov;28(9):1643-1649
pubmed: 30365456
Int J Gynecol Cancer. 2017 Nov;27(9):1833-1841
pubmed: 28816706
Am J Surg Pathol. 1995 Dec;19(12):1390-408
pubmed: 7503361
Cancer. 1979 Oct;44(4):1327-31
pubmed: 498013
Mod Pathol. 2006 Nov;19(11):1421-8
pubmed: 16980943